Trilobio Company Profile

Background

Overview

Trilobio, founded in 2021, is a biotechnology company headquartered in San Francisco, California. The company specializes in providing end-to-end automated synthetic biology platforms designed to enhance the efficiency and reproducibility of biological research. By integrating robotics, lab devices, and software, Trilobio aims to revolutionize laboratory automation, making it accessible and reliable for biologists across various disciplines.

Mission and Vision

Trilobio's mission is to empower scientists with full automation that is accessible and designed to serve them at its very core, giving scientists the same power over biology that computer scientists have over information. The company envisions a paradigm shift in biology that will lead to an explosion of research advances.

Industry Significance

In the biotechnology sector, Trilobio addresses critical challenges related to data quality and reproducibility in research. By offering a unified platform that combines robotics, lab devices, and software, the company seeks to streamline laboratory workflows, thereby accelerating scientific discovery and innovation.

Key Strategic Focus

Core Objectives

Trilobio focuses on developing a comprehensive automation platform that enables biologists to design and execute complex experiments with ease, without the need for extensive coding or calibration. The company's goal is to make lab automation effortless, reliable, and affordable, thereby enhancing the reproducibility and efficiency of biological research.

Areas of Specialization

The company specializes in synthetic biology, genetic engineering, and life sciences research, providing tools that automate various laboratory processes to improve data quality and reproducibility.

Key Technologies Utilized

Trilobio's platform includes:

Trilobot: A self-calibrating, modular robot designed to automate laboratory processes, enhancing reproducibility and efficiency in research.

Trilobio OS: An intelligent, no-code protocol design software that allows biologists to build and adjust complex experiments as quickly as writing in a lab notebook, without coding or endless calibration.

Primary Markets Targeted

Trilobio primarily targets academic research institutions, biotechnology companies, and life sciences laboratories that require reliable and scalable automation solutions to enhance their research capabilities.

Financials and Funding

Funding History

As of May 6, 2025, Trilobio has raised a total of $11 million across multiple funding rounds. The most recent funding round was a seed round in May 2025, where the company secured $8 million.

Notable Investors

Key investors include Initialized Capital, Argon Ventures, Lowercarbon Capital, Julian Capital, Juniper, Future Labs Capital, 1517 Fund, Alumni Ventures, Angel Squad, Sequel, Nucleus Capital, and Gaingels.

Utilization of Capital

The funds are intended to support the expansion of Trilobio's robotics capabilities and the development of no-code software features, enabling the integration of a growing portfolio of purpose-built lab devices and protocols into a single, fully automated platform.

Pipeline Development

Trilobio's primary product is the Trilobot, a self-calibrating, modular robot designed to automate various laboratory processes. The company has deployed its whole laboratory automation platform at leading biology labs across the United States, demonstrating a 33% increase in throughput and a 25% increase in data production compared to existing workflows.

Technological Platform and Innovation

Proprietary Technologies

Trilobot: A modular robot capable of automating various laboratory processes, enhancing reproducibility and efficiency in research.

Trilobio OS: An intelligent, no-code protocol design software that allows biologists to design and execute complex experiments without extensive coding or calibration.

Significant Scientific Methods

Trilobio employs a combination of robotics, software, and AI-driven capabilities to automate laboratory workflows, thereby improving data quality and reproducibility in biological research.

Leadership Team

Key Executives

Roya Amini-Naieni: CEO and Co-founder. Roya studied Math/Comp/Bio at Harvey Mudd College, where she founded a SynBio lab with grant funding from HMC’s president, conducted SynBio at UW, HMC, & Asimov, and founded the first non-collegiate iGEM team in WA state. She was named a 776 Fellow and recognized in Forbes 30 Under 30.

Maximilian Schommer: CTO and Co-founder. Maximilian studied Mechatronics at Olin, built over 50 novel personal projects, developed critical mechatronics and software for Relativity Space & Machina, and led a NASA research team. He was recognized in Forbes 30 Under 30.

Leadership Changes

As of the latest available information, there have been no significant changes or appointments within Trilobio's leadership team.

Competitor Profile

Market Insights and Dynamics

The laboratory automation market is experiencing significant growth, driven by the increasing need for reproducibility and efficiency in scientific research. Trilobio operates in a competitive landscape with companies such as Amyris, Syngenta, AskBio, Ginkgo Bioworks, and Antheia, among others.

Competitor Analysis

Amyris: Develops renewable products for industrial solutions.

Syngenta: Provides crop protection solutions and hybrid seeds for farming.

AskBio: Develops gene and protein therapies for treating various diseases.

Ginkgo Bioworks: Provides gene editing-based cultured ingredients for agriculture.

Antheia: Genetically engineers yeast cells to produce medicinal products.

Strategic Collaborations and Partnerships

Trilobio has established partnerships with leading biology labs across the United States to deploy its whole laboratory automation platform, demonstrating significant improvements in research efficiency and data production.

Operational Insights

Trilobio differentiates itself by offering an affordable and reliable lab automation solution that is accessible to a wide range of biologists, addressing common challenges such as inconsistent results, inflexible platforms, and high costs associated with traditional lab automation systems.

Strategic Opportunities and Future Directions

Trilobio's strategic roadmap includes expanding its portfolio of lab devices and protocols, enhancing the capabilities of its automation platform, and increasing market penetration in academic and commercial research sectors. The company's strengths in automation and reproducibility position it well to capitalize on the growing demand for efficient and reliable laboratory solutions.